High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits : pooled analyses of abrocitinib monotherapy studies in adults and adolescents. / Stander, S.; Bhatia, N.; Gooderham, M. J.; Silverberg, J.; Thyssen, J. P.; Biswas, P.; DiBonaventura, M.; Romero, W.; Farooqui, S. A.

In: Journal of the European Academy of Dermatology and Venereology, Vol. 36, No. 8, 06.05.2022, p. 1308-1317.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Stander, S, Bhatia, N, Gooderham, MJ, Silverberg, J, Thyssen, JP, Biswas, P, DiBonaventura, M, Romero, W & Farooqui, SA 2022, 'High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents', Journal of the European Academy of Dermatology and Venereology, vol. 36, no. 8, pp. 1308-1317. https://doi.org/10.1111/jdv.18170

APA

Stander, S., Bhatia, N., Gooderham, M. J., Silverberg, J., Thyssen, J. P., Biswas, P., DiBonaventura, M., Romero, W., & Farooqui, S. A. (2022). High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents. Journal of the European Academy of Dermatology and Venereology, 36(8), 1308-1317. https://doi.org/10.1111/jdv.18170

Vancouver

Stander S, Bhatia N, Gooderham MJ, Silverberg J, Thyssen JP, Biswas P et al. High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents. Journal of the European Academy of Dermatology and Venereology. 2022 May 6;36(8):1308-1317. https://doi.org/10.1111/jdv.18170

Author

Stander, S. ; Bhatia, N. ; Gooderham, M. J. ; Silverberg, J. ; Thyssen, J. P. ; Biswas, P. ; DiBonaventura, M. ; Romero, W. ; Farooqui, S. A. / High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits : pooled analyses of abrocitinib monotherapy studies in adults and adolescents. In: Journal of the European Academy of Dermatology and Venereology. 2022 ; Vol. 36, No. 8. pp. 1308-1317.

Bibtex

@article{2871bc4886c04dedbf4679a96d3e45e7,
title = "High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents",
abstract = "Background Once-daily abrocitinib treatment provided meaningful improvements in signs and symptoms of moderate-to-severe atopic dermatitis (AD) in randomized controlled studies. Objective To evaluate proportions of patients with responses meeting higher threshold efficacy responses than commonly used efficacy end points and to determine if these responses were associated with quality-of-life (QoL) benefits. Methods Data from a phase 2b (NCT02780167) and two phase 3 studies (NCT03349060/JADE MONO-1; NCT03575871/JADE MONO-2) in adult and adolescent patients (N = 942) with moderate-to-severe AD receiving once-daily abrocitinib 200 mg, abrocitinib 100 mg or placebo were pooled. Commonly used (Eczema Area and Severity Index [EASI]-75 and >= 4-point improvement in Pruritus Numerical Rating Scale [PP-NRS4]) and higher threshold efficacy end points (EASI-90 to",
keywords = "ECZEMA, PREVALENCE, SLEEP, RECOMMENDATIONS, GUIDELINES, MANAGEMENT, PRURITUS, HEALTH, ASTHMA, INDEX",
author = "S. Stander and N. Bhatia and Gooderham, {M. J.} and J. Silverberg and Thyssen, {J. P.} and P. Biswas and M. DiBonaventura and W. Romero and Farooqui, {S. A.}",
year = "2022",
month = may,
day = "6",
doi = "10.1111/jdv.18170",
language = "English",
volume = "36",
pages = "1308--1317",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0929-0168",
publisher = "Wiley-Blackwell",
number = "8",

}

RIS

TY - JOUR

T1 - High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits

T2 - pooled analyses of abrocitinib monotherapy studies in adults and adolescents

AU - Stander, S.

AU - Bhatia, N.

AU - Gooderham, M. J.

AU - Silverberg, J.

AU - Thyssen, J. P.

AU - Biswas, P.

AU - DiBonaventura, M.

AU - Romero, W.

AU - Farooqui, S. A.

PY - 2022/5/6

Y1 - 2022/5/6

N2 - Background Once-daily abrocitinib treatment provided meaningful improvements in signs and symptoms of moderate-to-severe atopic dermatitis (AD) in randomized controlled studies. Objective To evaluate proportions of patients with responses meeting higher threshold efficacy responses than commonly used efficacy end points and to determine if these responses were associated with quality-of-life (QoL) benefits. Methods Data from a phase 2b (NCT02780167) and two phase 3 studies (NCT03349060/JADE MONO-1; NCT03575871/JADE MONO-2) in adult and adolescent patients (N = 942) with moderate-to-severe AD receiving once-daily abrocitinib 200 mg, abrocitinib 100 mg or placebo were pooled. Commonly used (Eczema Area and Severity Index [EASI]-75 and >= 4-point improvement in Pruritus Numerical Rating Scale [PP-NRS4]) and higher threshold efficacy end points (EASI-90 to

AB - Background Once-daily abrocitinib treatment provided meaningful improvements in signs and symptoms of moderate-to-severe atopic dermatitis (AD) in randomized controlled studies. Objective To evaluate proportions of patients with responses meeting higher threshold efficacy responses than commonly used efficacy end points and to determine if these responses were associated with quality-of-life (QoL) benefits. Methods Data from a phase 2b (NCT02780167) and two phase 3 studies (NCT03349060/JADE MONO-1; NCT03575871/JADE MONO-2) in adult and adolescent patients (N = 942) with moderate-to-severe AD receiving once-daily abrocitinib 200 mg, abrocitinib 100 mg or placebo were pooled. Commonly used (Eczema Area and Severity Index [EASI]-75 and >= 4-point improvement in Pruritus Numerical Rating Scale [PP-NRS4]) and higher threshold efficacy end points (EASI-90 to

KW - ECZEMA

KW - PREVALENCE

KW - SLEEP

KW - RECOMMENDATIONS

KW - GUIDELINES

KW - MANAGEMENT

KW - PRURITUS

KW - HEALTH

KW - ASTHMA

KW - INDEX

U2 - 10.1111/jdv.18170

DO - 10.1111/jdv.18170

M3 - Journal article

C2 - 35462428

VL - 36

SP - 1308

EP - 1317

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0929-0168

IS - 8

ER -

ID: 314160453